Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac2c17e532220d91aca9a28ef60f178b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B09B2101-68 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B09B3-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7092 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
filingDate |
2002-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_491b138274350df89e0856fbff874dc1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53c344249c7be0257680ed79569414c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d692cd7be069c082819c117dc0177466 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e0dc26e546513d55ff999fabf6c1c71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43439f80b966fb2c0a19c9ce9ac8a7ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6e1e526a59fba0cbb731ed6bbb455f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bab03328b3c5e86be4224cd727815388 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03a467f4fc8a4a7d3c7ea2c86ac328d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d927283ea7f3afbc84f3c0acffe7f98d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72872485a2ca2f7e1884f437cbf25dc8 |
publicationDate |
2005-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1397095-A4 |
titleOfInvention |
TRANSDERMAL SYSTEMS CONTAINING OPIOID RESISTANT TO MISUSE |
abstract |
The present invention relates to transdermal dosage form (Fig. 1-3) comprising at least one activating agent and at least one inactivating agent. The dosage form (Fig. 1-3) releases the inactivating agent upon disruption of the dosage form (Fig. 1-3) thereby preventing or hindering misuse of the active agent contained in the dosage form (Fig. 1-3). |
priorityDate |
2001-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |